Table 6.
Nanotechnologies employed in clinical studies for glioblastoma, with type of intervention used are stated.
| Nanotechnology | Type of Intervention | Reference |
|---|---|---|
| NU-0129: Spherical Nucleic Acid (SNA) platform consisting of nucleic acids arranged on the surface of a small spherical gold nanoparticle that targets cancer cells, via the BBB, to inhibit the activity of the Bcl2L12 gene to induce apoptosis | Therapeutic—siRNA delivery | [80] |
| SGT-53: complex of cationic liposome encapsulating a normal human wild-type p53 DNA sequence in a plasmid backbone for delivery to tumor cells via the BBB. | Therapeutic—drug (Temozolomide) and gene Delivery | [81] |
| 2B3- 101: Glutathione pegylated liposomal doxorubicin hydrochloride | Therapeutic—drug delivery | [82] |
| BrUOG 329 (Onivyde): Nanoliposomal Irinotecan with enhanced ability to cross the BBB | Therapeutic—drug delivery | [83] |
| NanoBB- 1-Dox: nanoparticle-based formulation of doxorubicin, which enables passage of the drug across the BBB and delivery to the tumor inside the brain | Therapeutic—drug delivery | [84] |
| NanoTherm®: superparamagnetic iron oxide nanoparticles (SPIONS) | Therapeutic—Hyperthermia | [30,31,32,85] |
| EnGeneIC delivery vehicle (EDV): Novel nanoparticle (minicell) made from Salmonella typhi that encapsulates doxorubicin and targets Epithelial growth factor receptor (EGFR) by Vectibix | Therapeutic—drug delivery | [39] |
| Pegylated liposomal doxorubicin (Caelyx™, PEG-Dox) | Therapeutic—drug delivery | [33,34,35] |
| Myocet®: a non-pegylated liposomal doxorubicin | Therapeutic—drug delivery | [86] |
| Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs- dox) in High-grade Gliomas (GBM-LIPO) | Therapeutic—drug delivery | [87] |